SCHEMBL5578689

SCHEMBL5578689

O=C(c1ccccc1F)N1CC2(CCN(c3ccc(Cl)cc3)CC2)c2cc(Cl)ccc21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
HTT P42858 2/20 0.43
ALDH1A1 P00352 5/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MGLL Q99685 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
LMNA P02545 3/20 0.38
MAPT P10636 4/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
MCL1 Q07820 1/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578704 0.96 NOTUM (0.49) NOTUMHTTALDH1A1L3MBTL1MGLL
SCHEMBL5578851 0.94 NOTUM (0.48) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5579107 0.93 NOTUM (0.48) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5578888 0.93 NOTUM (0.44) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5578894 0.92 NOTUM (0.46) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5777701 0.91 NOTUM (0.45) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5578681 0.91 NOTUM (0.50) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5578835 0.90 NOTUM (0.49) NOTUMHTTALDH1A1L3MBTL1MGLL
SCHEMBL5579066 0.90 NOTUM (0.43) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5578596 0.82 NOTUM (0.46) NOTUMHTTALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US claimed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL NOTUM 3318/4885HTT 1591/4885ALDH1A1 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.